Nemaura Medical (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has entered in to a definitive joint Collaboration Agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA). Nemaura previously signed a licensing agreement with …

Nemaura Medical (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT^® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has entered in to a definitive joint Collaboration Agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT^® in the European Economic Area (EEA). Nemaura previously signed a licensing agreement with DBE for the commercialization of sugarBEAT^® in the United Kingdom and Ireland.

As quoted in the press release:

“We are pleased to extend our relationship with DBE and believe their expertise will play an important role in the commercialization of sugarBEAT^®.” said Dr. Faz Chowdhury, Chairman and CEO of Nemaura. “We expect to receive CE approval for sugarBEAT^® in the coming months and anticipate an initial launch in the UK later this year spearheaded directly by DBE, followed by a broader roll-out to select European markets via sub-distributors.”
DBE was founded by Dr. Dallas Burston (MBBS), a pharmaceutical marketing entrepreneur specializing in selling breakthrough medical products into European markets. Dr. Burston has founded and rapidly grown several European medical companies which were subsequently acquired by large pharmaceutical companies.

Click here to read the full press release.